Celltrion UK has officially opened its new UK headquarters at the Charter Building in Uxbridge, UK, reinforcing the company’s dedication to long-term growth and partnership in the UK market.
Strategically located in the heart of Uxbridge, the new office will serve as Celltrion UK’s central hub for UK operations. This move places South Korean firm Celltrion among a growing list of life sciences companies including Regeneron, Amgen, Gilead Sciences, Daiichi Sankyo, that have established presence in Uxbridge – emerging as a leading hub for biotechnology and pharmaceutical innovation.
Speaking at the opening ceremony, Hyoung-Ki Kim, CEO and Vice Chairman of Celltrion, said, “The opening our new UK office marks a pivotal milestone in Celltrion UK history. This demonstrates our strong commitment to the UK, a strategic market for our growth. We are here for the long term and are invested in the future of biosimilars in the UK. We look forward to continued collaboration with local institutions and regulatory bodies to ensure sustainable access to high-quality biologic treatments.”
The new headquarters also reflects continued growth for Celltrion UK, which has expanded its headcount by 20% over the past year. With an exciting pipeline of new products spanning across multiple therapeutic areas including allergy, endocrinology, ophthalmology and immunology anticipated over the coming years, the company expects further recruitment and investment in the coming years.
This move is the latest chapter in Celltrion’s long-term vision for the UK, demonstrating its dedication to being a trusted healthcare partner, a contributor to the UK economy, and a key player in the global biosimilars market.
